Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856

STOCKHOLM, June 29, 2022 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced th...